Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ: ACLX )

51.25 -4.97 (-8.84%)
Streaming Delayed Price Updated: 12:55 PM EST, Dec 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 Next >
How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer
This biotech stock launched in February to work on CAR-T treatments. 
Via Investor's Business Daily
70 Biggest Movers From Friday
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... 
Via Benzinga
Expert Ratings for Arcellx
Analysts have provided the following ratings for Arcellx (NASDAQ:ACLX) within the last quarter: 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 198 companies made new 52-week lows. Key Facts About Today's 52-Week Highs And Lows: Alibaba Group Holding (NYSE:BABA) is the largest... 
Via Benzinga
CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19
CAR-T company Arcellx Inc (NASDAQ: ACLX) priced its IPO at  
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma
Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical study of ACLX-001 for patients with Relapsed or Refractory Multiple Myeloma... 
Via Benzinga
Arcellx, Inc To Start Trading Tomorrow
ARCELLX, INC (NASDAQ:ACLX) IPO will take place February, 04 on the NASDAQ exchange under the ticker ACLX. The company is offering shares at an expected price between $15.00 and $... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 123 stocks made new 52-week lows. 
Via Benzinga
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 29 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
Opening Day: AN2 Therapeutics Rises In Public Debut After Upsized IPO
Shares of AN2 Therapeutics rose over 15% in its trading debut on Friday following an upsized initial public offering. This was only the second initial public offering this month, as the IPO market... 
Via Talk Markets
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 52 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 39 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap to set a... 
Via Benzinga
BofA Initiates Arcellx With Buy On Its Novel Therapy Approach
Arcellx (NASDAQ: ACLX) is advancing into pivotal testing (by year-end 2022) of its B-cell maturation antigen (BCMA) directed combination antiretroviral therapy (CART), known... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Hanesbrands And 2 Other Stocks Bought By Insiders
US stock futures traded lower this morning after recording sharp losses in the previous session. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Insiders Buy Over $43M Of 4 Stocks
US stock futures traded mixed this morning ahead of the inflation data due today. Investors, meanwhile, focused on some notable insider trades 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 71 stocks hit new 52-week lows. Noteable 52-Week Lows: 3M (NYSE:MMM) was the biggest company in terms of market cap to set a new 52-week low. OceanPal (... 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
Opening Day: Arcellx Raises $124M In Wall Street Debut
Cell therapy biotech Arcellx made its public debut on Friday, raising $124 million to bankroll its multiple myeloma CAR-T study. 
Via Talk Markets
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.